Kazia grants 250,000 options to Chief Scientist

Kazia Therapeutics Ltd reported that Chief Scientific Officer Sudha Rao received a grant of 250,000 employee stock options over ADSs.

Rhea-AI Filing Summary

Kazia Therapeutics Ltd reported that Chief Scientific Officer Sudha Rao received a grant of 250,000 employee stock options over ADSs. The options have an exercise price of $18.48 per ADS, were granted for no cash consideration, and are held directly.

One-third of the options vest on April 13, 2026, with the remaining two-thirds vesting in equal yearly tranches on each anniversary of that date, subject to continued service. All options will be forfeited if she voluntarily leaves before the first anniversary. Any unexercised options expire on June 19, 2029. After this grant, she holds 250,000 options in total.

Insider Trade Summary

Grant/Award: 250,000 shares

Grant/Award 1 txn

Insider Rao Sudha

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	250,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 250,000 contracts (Direct)

Footnotes (1)

1. F1. Represents the grant to the Reporting Person of 250,000 options over ADSs at an exercise price of $18.48 per ADS. One-third of the options vest on April 13, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029.

Key Figures

Options granted: 250,000 options Exercise price: $18.48 per ADS Vesting start date: April 13, 2026 +2 more

5 metrics

Options granted 250,000 options Employee stock options over ADSs granted to Chief Scientific Officer

Exercise price $18.48 per ADS Exercise price for the granted employee stock options

Vesting start date April 13, 2026 One-third of options vest on the commencement date

Total options after grant 250,000 options Total derivative holdings following the reported transaction

Expiration date June 19, 2029 Date on which any unexercised options will lapse

Key Terms

Employee Stock Option (right to buy), ADSs, exercise price, vesting, +1 more

5 terms

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

ADSs financial

"options over ADSs at an exercise price of $18.48 per ADS"

exercise price financial

"at an exercise price of $18.48 per ADS"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"One-third of the options vest on April 13, 2026 and the remaining two-thirds vest"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"The options were granted for no consideration and expire on June 19, 2029"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kazia Therapeutics (KZIA) disclose for Sudha Rao?

Kazia Therapeutics disclosed that Chief Scientific Officer Sudha Rao received a grant of 250,000 employee stock options over ADSs. These options were granted for no cash consideration and represent a compensation award rather than an open-market share purchase or sale.

What is the exercise price of Sudha Rao’s new Kazia (KZIA) stock options?

The granted options have an exercise price of $18.48 per ADS. This is the fixed price at which she can buy Kazia ADSs if the options vest and are exercised before their scheduled expiration date in 2029, assuming continued employment and satisfaction of vesting conditions.

How do Sudha Rao’s Kazia (KZIA) stock options vest over time?

One-third of the 250,000 options vest on April 13, 2026, the stated commencement date. The remaining two-thirds vest in equal yearly tranches on each anniversary of that date, creating a multi-year vesting schedule that ties the award to her ongoing service at Kazia.

When do Sudha Rao’s newly granted Kazia (KZIA) options expire?

The options granted to Sudha Rao expire on June 19, 2029. Any options that have not been exercised by that date will lapse, meaning she loses the right to buy ADSs at the $18.48 exercise price after the expiration date passes.

What happens to the Kazia (KZIA) options if Sudha Rao leaves early?

All options held by Sudha Rao will be forfeited if she voluntarily departs before the first anniversary of the April 13, 2026 commencement date. This condition encourages at least one year of continued service before she can retain any portion of the award.

How many Kazia (KZIA) options does Sudha Rao hold after this grant?

After this grant, Sudha Rao holds a total of 250,000 employee stock options over Kazia ADSs. This entire amount reflects the new award reported, as indicated by the post-transaction derivative holdings disclosed in the insider transaction summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 06:47 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rao Sudha

(Last) (First) (Middle)

THREE INTERNATIONAL TOWERS, LEVEL 24

300 BARANGAROO AVENUE

(Street)

SYDNEY NSW 2000

(City) (State) (Zip)

AUSTRALIA

(Country)

2. Issuer Name and Ticker or Trading Symbol
KAZIA THERAPEUTICS LTD [ KZIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol
[KZIA]

3. Date of Earliest Transaction (Month/Day/Year)
06/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$18.48	06/19/2026		A		250,000(1)		(1)	(1)	ADSs	250,000	$0	250,000	D

Explanation of Responses:

1. Represents the grant to the Reporting Person of 250,000 options over ADSs at an exercise price of $18.48 per ADS. One-third of the options vest on April 13, 2026 (the "Commencement Date") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029.

	/s/ Sudha Rao	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)